CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) Revenue
Annual & quarterly revenue history · segment & region breakdown
CRSP · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCRISPR Therapeutics AG trailing twelve-month (TTM) revenue is $0.00B, a decrease of 89.97% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2014 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.03B | -89.97% |
| 2024-12-31 | $0.04B | -$0.34B | -90.54% |
| 2023-12-31 | $0.37B | +$0.37B | +84762.39% |
| 2022-12-31 | $0.00B | -$0.91B | -99.95% |
| 2021-12-31 | $0.91B | +$0.91B | +126893.18% |
| 2020-12-31 | $0.00B | -$0.29B | -99.75% |
| 2019-12-31 | $0.29B | +$0.29B | +9169.85% |
| 2018-12-31 | $0.00B | -$0.04B | -92.38% |
| 2017-12-31 | $0.04B | +$0.04B | +693.90% |
| 2016-12-31 | $0.01B | +$0.00B | +1990.69% |
Compare revenue vs peers
BiotechnologyCompare CRSP revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income CRISPR Therapeutics AG receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
CRISPR Therapeutics AG reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from CRISPR Therapeutics AG's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CRSP revenue · 4 questionsCRSP's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 89.97% year-over-year from $0.00B in FY2025.
▸ Source: FMP · CRISPR Therapeutics AG SEC filings · GAAP · CRISPR Therapeutics AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026